**Supplementary Table 1** - Clinical and pathological characteristics of the study cohort stratified by preoperative and postoperative neutrophil lymphocyte ratio status (no elevation, preoperative or postoperative elevation, both preoperative and postoperative elevation, n=346)

| Variable                        | No elevation (n=110) | Preoperative or postoperative elevation (n=126) | Preoperative and postoperative elevation (n=110) | p-value | Adjusted p-value |
|---------------------------------|----------------------|-------------------------------------------------|-------------------------------------------------|---------|------------------|
| Age in years (median [IQR])     | 67.26 [60.69, 73.37] | 70.28 [64.34, 75.86]                            | 70.38 [64.85, 77.32]                            | 0.005   | 0.015            |
| Sex (%)                         |                      |                                                 |                                                 |         |                  |
| Female                          | 31 (28.2)            | 25 (19.8)                                       | 22 (20.0)                                       | 0.242   | 0.44             |
| Male                            | 79 (71.8)            | 101 (80.2)                                      | 88 (80.0)                                       |         |                  |
| CCI (%)                         |                      |                                                 |                                                 |         |                  |
| <3                              | 91 (82.7)            | 93 (73.8)                                       | 68 (61.8)                                       | 0.002   | 0.009            |
| ≥3                              | 19 (17.3)            | 33 (26.2)                                       | 42 (38.2)                                       |         |                  |
| Local clinical stage (n=344)    |                      |                                                 |                                                 |         |                  |
| NMIBC                           | 16 (14.8)            | 20 (15.9)                                       | 14 (12.7)                                       | 0.795   | 0.795            |
| MIBC                            | 92 (85.2)            | 106 (84.1)                                      | 96 (87.3)                                       |         |                  |
| T-stage* (%)                    |                      |                                                 |                                                 | <0.001  | 0.004            |
| T0-T1                           | 53 (48.2)            | 46 (36.5)                                       | 27 (24.5)                                       |         |                  |
| T2                              | 23 (20.9)            | 19 (15.1)                                       | 17 (15.5)                                       |         |                  |
| T3-T4                           | 34 (30.9)            | 61 (48.4)                                       | 66 (60.0)                                       |         |                  |
| Lymph node involvement* (%)     |                      |                                                 |                                                 | 0.293   | 0.44             |
| Negative                        | 84 (76.4)            | 99 (78.6)                                       | 77 (70.0)                                       |         |                  |
| Positive                        | 26 (23.6)            | 27 (21.4)                                       | 33 (30.0)                                       |         |                  |
| Surgical margin status (%)      |                      |                                                 |                                                 | 0.525   | 0.61             |
| Negative                        | 102 (92.7)           | 117 (92.9)                                      | 98 (89.1)                                       |         |                  |
| Positive                        | 8 (7.3)              | 9 (7.1)                                         | 12 (10.9)                                       |         |                  |
| Neoadjuvant treatment (%)       |                      |                                                 |                                                 | 0.101   | 0.23             |
| No                              | 58 (52.7)            | 83 (65.9)                                       | 62 (56.4)                                       |         |                  |
| Yes                             | 52 (47.3)            | 43 (34.1)                                       | 48 (43.6)                                       |         |                  |
| Adjuvant treatment (%)          |                      |                                                 |                                                 | 0.54    | 0.61             |
| No                              | 82 (74.5)            | 101 (80.2)                                      | 88 (80.0)                                       |         |                  |
| Yes                             | 28 (25.5)            | 25 (19.8)                                       | 22 (20.0)                                       |         |                  |

IQR = interquartile range; CCI = Charlson Comorbidity Index; NMIBC = non-muscle invasive bladder cancer; MIBC = muscle invasive bladder cancer; NA = not available

* According to pathology findings after surgery